
Results 1 - 20 of 167 in Keryx Biopharmaceuticals
NASDAQ Active Stock Watch List: Keryx Biopharmaceuticals Inc....
Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Keryx Biopharmaceuticals Inc. Comment?
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Ariad Pharmaceuticals...
Growing Stock Report expands its Biotech Gainers Weekly Watch List adding Keryx Biopharmaceuticals Inc. Comment?
3 Biotech Stocks With Potential
w/Photo
... recent examples of the high levels of volatility that small cap biotech investing can throw at you. Keryx Biopharmaceuticals ( KERX ) is an early stage biotech company that had been focusing on developing a treatment for kidney disease, called ... Comment?
Technical Stock Breakout Watch: Keryx Biopharmaceuticals
The online StockConsultant latest screen has found a biotech company that provides drugs for the treatment of cancer and renal diseases Keryx Biopharmaceuticals stock under a breakout watch above 8.77. KERX stock price is up 5.6% to 8.68 on 50.3% higher volume and is trying to break over double resistance. Comment?
Keryx Biopharmaceutical's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Greetings and welcome to the Keryx Biopharmaceuticals Investor Conference Call. At this time, all participants are in a listen-only mode. Comment?
Keryx: A Small Biotech With Many Catalysts
... holding the shares of Sarepta Therapeutics ( SRPT ), which we reviewed unfavorably on April 24th . Keryx Biopharmaceuticals is developmental stage biopharmaceutical company that's focused on the acquisition, development and commercialization of ... Comment?
Keryx Biopharmaceuticals Announces First Quarter 2013 Financial Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! NEW YORK, May 6, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. Comment?
Keryx Biopharmaceuticals (KERX) Posts Quarterly Earnings, Misses Estimates By $0.02 EPS
Keryx Biopharmaceuticals issued its quarterly earnings data on Wednesday. The company reported EPS for the quarter, missing the Thomson Reuters consensus estimate of by $0.02, AnalystRatings.Net reports. Comment?
Whisper Number Impact: Earnings Preview For Keryx Biopharmaceuticals
Keryx Biopharmaceuticals is expected to report earnings on Wednesday, May 8th. The whisper number is -$0.01, in-line with the analysts' estimate. Comment?
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease , today announced its results for the first quarter ended March 31, 2013. Comment?
GSK, AZN, KERX, and RPTP Early Briefing and Review
... data. Among the major movers were GlaxoSmithKline Plc (NYSE: GSK), AstraZeneca Plc (NYSE: AZN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Raptor Pharmaceutical Corp. (NASDAQ: RPTP). StockCall has released free charting and technical research ... Comment?
Key ETF Performance In April And Year To Date
The first four months of the trading year are now behind us, and the "big three" of U.S. market indices are all now up more than 10% year to date. Comment?
NewLink Genetics: Looking To Join The Industry's Largest Movers
... look at the last year alone, there have been countless valuation-changing moves in biotechnology. Keryx Biopharmaceuticals ( KERX ) saw a two-day period where its stock more than doubled after reporting Phase 3 data. Sarepta Therapeutics ( SRPT ) ... Comment?
Hot Stocks: Whirlpool Corporation, Allegheny Technologies...
... rating in a report released on April 16. How Should Investors Trade SRPT Now? Find Out Here Keryx Biopharmaceuticals (NASDAQ:KERX) shares declined 2.53% to $8.10. The company, on Marc h 11, announced its results for the fourth quarter and year ended ... Comment?
Keryx Biopharmaceuticals and Nuance Communications Analysis:
Keryx Biopharmaceuticals traded at $ 8.32 in the last session, which is +0.29 . The stock has a Range of 8.06 - 8.64. The stock has a 52 week low and high of 1.34 - 9.98 respectively. Comment?
Stock Breakout Watch: Keryx Biopharmaceuticals (KERX), Target 10.5
The online StockConsultant latest screen has found provider of drugs to for the treatment of cancer Keryx Biopharmaceuticals stock under a breakout watch above 8.81. KERX stock price is up 4.9% to 8.42 with 89.3% higher volume and is completing a string of two strong days higher. Comment?
Traders Favorite: Keryx Biopharmaceuticals, McDonald's Corporation,...
Keryx Biopharmaceuticals shares gained 5.48% to $8.47. The company, on March 11, announced its results for the fourth quarter and year ended December 31, 2012. Comment?
Keryx, Zerenex, And IP Protection: A PropThink Conference Call
... a leading patent attorney and former staff at the USPTO. The conference call centered around Keryx Biopharmaceuticals ( KERX ) and its lead drug candidate, Zerenex, which has come under scrutiny as questions have arisen about the drug's existing ... Comment?
Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Celgene Corporation...
Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Keryx Biopharmaceuticals Inc. Comment?
... with over 4.3 million shares that have exchanged hands, will ACAD continue to push? Stay tuned. Keryx Biopharmaceuticals (NASDAQ:KERX) is slowly trending north, trading at an intraday of $8.4998 (+5.85%) with over 3.6 million share exchanged, will ... Comment?